Subscribe
shutterstock_2169738405_t_schneider
T. Schneider / Shutterstock.com
21 July 2022AmericasStaff writer

Generic maker pays $145m to settle antitrust suit

California company resolves pay-for-delay issue over opioids | Allegations were brought by direct purchasers eight years ago.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Irish pharma company prevails in US pay-for-delay case
5 July 2022   The ruling marks the latest development of a long-running dispute over the alleged delay of a generic version of the blockbuster painkiller.
Big Pharma
Endo, Impax face class-action over antitrust claims
7 June 2021   Endo International and Amneal Pharmaceuticals’ subsidiary, Impax Laboratories, have failed to prevent antitrust claims over a patent settlement from going to trial.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Americas
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Americas
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Big Pharma
Irish pharma company prevails in US pay-for-delay case
5 July 2022   The ruling marks the latest development of a long-running dispute over the alleged delay of a generic version of the blockbuster painkiller.
Big Pharma
Endo, Impax face class-action over antitrust claims
7 June 2021   Endo International and Amneal Pharmaceuticals’ subsidiary, Impax Laboratories, have failed to prevent antitrust claims over a patent settlement from going to trial.

More on this story

Big Pharma
Irish pharma company prevails in US pay-for-delay case
5 July 2022   The ruling marks the latest development of a long-running dispute over the alleged delay of a generic version of the blockbuster painkiller.
Big Pharma
Endo, Impax face class-action over antitrust claims
7 June 2021   Endo International and Amneal Pharmaceuticals’ subsidiary, Impax Laboratories, have failed to prevent antitrust claims over a patent settlement from going to trial.

More features

Startup challenges rival over brain monitoring tech at ITC
UKIPO rejects Boehringer’s SPC for horse inhaler
WilmerHale gains partner with ‘deep expertise’
Bayer, Orion take on Indian generic over $117bn drug
‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court